For years, metformin has been the go-to first-line oral medication for patients newly diagnosed with type 2 diabetes. But ...

The analysis of 3 dozen studies found similarities and differences in motivating factors for and against clinical trial ...

The antibody is tailored for RA patients who have not responded well to existing treatments, including anti-tumour necrosis factor (TNF) therapies. The first-in-human, adaptive design, randomised ...

"ABO21009 is the first antibody of its class to enter clinical trials in Europe and we believe it has great potential as a disease-modifying treatment for RA due to its multi-pronged ... material ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

AbolerIS Pharma has dosed the Phase I study’s first cohort subjects with its humanised anti-CD45 receptor-like protein C ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment. Physicians reported not giving recommended treatment based on guidelines and safety ...

"ABO21009 is the first antibody of its class to enter clinical trials in Europe and we believe it has great potential as a disease-modifying treatment for RA due to its multi-pronged mechanism of ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

A study of more than 100 patients found that immunotherapy can cure a rare type of cancer in various tumor sites without ...